
## Oncocount RGCC ™

## Results






RGCC




Ioannis Papasotiriou M.D., PhD Head of molecular medicine dpt of R.G.C.C -Research Genetic Cancer Centre International GmbH Baarerstr 95, 6300, Zug, Switzerland Tel: +41-41-7250560 Website: www.rgcc-group.com E-mail:medical@rgcc-genlab.com



## Index of circulating cells number

If over limit: Advanced or progression of disease. If less than limit: Early disease or disease is responding to a treatment plan.



Ioannis Papasotiriou M.D., PhD Head of molecular medicine dpt of R.G.C.C -Research Genetic Cancer Centre International GmbH Baarerstr 95, 6300, Zug, Switzerland Tel: +41-41-7250560 Website: www.rgcc-group.com E-mail:medical@rgcc-genlab.com



The final results after the isolation procedure are presented below

We notice that after isolation procedure there are remaining malignant cells.

The concentration of these cells was isolated 3.3 cells/7.5 ml, SD +/- 0.3 cells.

**Disclaimers** 

\*This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.No test is 100% accurate.

\*The methodology has a sensitivity of 86,2% and specificity of 83,9%

Sincerely,

Ioannis Papasotiriou MD., PhD Head of molecular medicine dpt. of R.G.C.C.-Research Genetic Cancer Centre International GmbH